More Information on 'Horizon Discovery Group plc'

Horizon Discovery is a company that provides products and services for gene editing, gene modulation, and functional genomics. The company's core business involves the design, development, and manufacture of RNA interference (RNAi) reagents, including small interfering RNA (siRNA) and microRNA (miRNA) products. These reagents are used by researchers to study gene function and silence specific genes in cells. Horizon Discovery also offers a range of cell lines, including those that are pre-engineered and ready to use, as well as reference standards for oncology research, such as the Mimix Geni somatic cancer reference standards. The company's products are designed to support research in various fields, including cancer, neuroscience, and immunology, and are used in applications such as gene knockdown, gene editing, and high-throughput screening.

About Horizon Discovery Group plc
Horizon has been ranked as one of the fastest growing biotechnology companies in Europe by Deloitte with a staff of more than 80 people spread across scientific, operations and commercial functions and accommodated within a 17,800 sq. ft. state-of-art facility in Cambridge, UK. The company has grown rapidly and now has a customer base comprising almost 800 organisations including major pharmaceutical, biotech and diagnostic companies as well as leading academic research centres. Horizon was named the 2012 East of England Business of the Year and the company’s success in supplying its products and services in overseas markets led to the company receiving the 2012 Queen’s Award for Enterprise in International Trade.